ReviewJournal of blood medicine2021

Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma.

Karun Neupane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.